Context Therapeutics Q2 Loss Widens to $14.6M, Discontinues CT-95 Program
CNTX sits 21% above its 52-week low of $0.545.
Summary
Context Therapeutics reported a Q2 net loss of $14.6 million, wider than the prior year, driven by a $6.5 million charge for amending the BioAtla license and higher CTIM-76 costs. The company discontinued its CT-95 program to focus resources on CTIM-76 and CT-202. Cash of $43 million is expected to fund operations into Q4 2027, with initial clinical readouts from both programs beginning in Q2 2027 and a Phase 1b dose expansion trial for CTIM-76 planned for Q1 2027. This follows positive interim Phase 1 results for CTIM-76 in June and a Nasdaq delisting notice in July, adding pressure to advance the pipeline efficiently.
At the time of this announcement, CNTX was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.7M. The 52-week trading range was $0.55 to $3.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.